Earnings summaries and quarterly performance for BIOMERICA.
Executive leadership at BIOMERICA.
Board of directors at BIOMERICA.
Research analysts covering BIOMERICA.
Recent press releases and 8-K filings for BMRA.
Biomerica Reports Q2 FY2026 Financial Results and Strategic Progress
BMRA
Earnings
Product Launch
New Projects/Investments
- Biomerica reported net sales of $1.21 million for the second quarter of fiscal 2026, a decrease from the prior year, while its year-to-date net loss improved to $1.31 million compared to $2.27 million in the prior year period.
- The company is executing a strategic pivot to higher-value, higher-margin diagnostic-guided therapy products, with management anticipating significant margin expansion from new initiatives like inFoods® IBS and partnerships.
- Subsequent to the quarter ended November 30, 2025, the Centers for Medicare & Medicaid Services (CMS) established a national Medicare payment rate of $300 for Biomerica’s inFoods® IBS test, effective January 1, 2026, which is expected to expand patient access.
- Biomerica strengthened its financial foundation, with operating expenses declining 4% year-to-date, working capital improving by 14.7%, and its cash position increasing to $2.5 million.
Jan 14, 2026, 10:17 PM
Biomerica Announces CMS Medicare Payment Rate for inFoods® IBS Test
BMRA
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a national Medicare payment rate of $300 for its inFoods® IBS test under the Clinical Laboratory Fee Schedule (CLFS).
- This payment rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.
- The $300 CLFS payment rate is considered a significant commercial milestone, providing a foundation for negotiations with private insurers and aiming to expand patient access.
- The inFoods® IBS test addresses a substantial market, as irritable bowel syndrome affects approximately 10% to 15% of adults in the United States, representing over 30 million potential patients.
Dec 23, 2025, 1:19 PM
Biomerica Receives Egyptian Drug Authority Authorization for Screening Test Portfolio
BMRA
Product Launch
New Projects/Investments
- Biomerica, Inc. announced that the Egyptian Drug Authority (EDA) has granted authorization for its complete portfolio of rapid tests, enabling broad access to early detection tools for conditions associated with cancers and chronic diseases across Egypt.
- The authorized portfolio includes tests for colorectal disease, breast self-exam, prostate disease, kidney disease, and H. pylori infection.
- These tests are designed for rapid, easy-to-use, and cost-effective screening for mass and individual use, providing quick results within minutes and eliminating the need for laboratory sample processing.
- This authorization strengthens Biomerica's strategic expansion across the Middle East and North Africa (MENA) region.
Dec 11, 2025, 1:08 PM
Biomerica's Fortel® Kidney Test Approved for Home Use in UAE
BMRA
Product Launch
New Projects/Investments
- Biomerica's Fortel® Kidney Test has received approval for home use from the United Arab Emirates (UAE) Ministry of Health and Prevention.
- This rapid, 10-minute diagnostic test detects early kidney damage by identifying low levels of albumin in urine.
- The approval is particularly relevant for the UAE, where diabetes affects approximately one in four UAE nationals and hypertension has an overall prevalence of about 31%, both being major risk factors for chronic kidney disease.
- This regulatory milestone expands access to diagnostic tools and strengthens Biomerica's presence in the Middle East, with the test planned for availability in pharmacies, clinics, and hospitals throughout the UAE.
Sep 3, 2025, 12:19 PM
Biomerica Reports Fiscal 2025 Year-End Results
BMRA
Earnings
Demand Weakening
Product Launch
- Biomerica reported net sales of $5.3 million for the fiscal year ended May 31, 2025, a slight decrease from $5.4 million in the prior year, primarily due to global tariff-related uncertainties and a shift in product mix.
- The company significantly improved its financial efficiency, reducing operating expenses by over $1.3 million and improving its operating loss to $5.1 million from $6.4 million year-over-year. Cash used in operating activities also improved to $3.8 million from $5.3 million in the prior year.
- Key strategic advancements include the American Medical Association issuing a Proprietary Laboratory Analyses (PLA) code for Biomerica’s inFoods® IBS test, advancing its reimbursement pathway, and the introduction of a new patient self-collection system for inFoods® IBS to expand access.
Aug 29, 2025, 9:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more